TWST - Genomics firm Twist Bioscience's Momentum To Continue Throughout 2024 Analyst Says | Benzinga
Thursday, Twist Bioscience Corporation (NASDAQ:TWST) reported a second-quarter EPS loss of $(0.79), better than a loss of $(1.04) a year ago and the consensus of $(0.81).
The synthetic biology and genomics company reported sales of $75.3 million, up 25% Y/Y, beating the consensus of $70.66 million. Orders increased to $93.2 million, up 45% Y/Y.
Gross margin for the second quarter of fiscal 2024 increased to 41% compared to 31% a year ago.
Shipped products to 2,253 customers, up from 2,100 a year ago. Shipped approximately 193,000 genes, up from approximately 152,000 a year ago.
Guidance: Twist Bioscience expects third-quarter revenue of $77 million (Est $73.8 million) and $77 million-$80 million for the fourth quarter (Est $77.2 million).
The company ...